Episode Details
Back to Episodes
Verzenios Shifts Hands in China | Business and Finance News
Description
Eli Lilly and Innovent Biologics are teaming up to revolutionize access to Verzenios in China, with Innovent handling local sales and marketing while Lilly retains manufacturing and R&D. This strategic shift boosts patient reach for a critical breast cancer drug already covered by national insurance and generating over $221 million annually. With a generic version pending patent expiry in late 2029, the partnership leverages Innovent’s market muscle and Lilly’s global innovation—marking their eighth collaboration and expanding their joint portfolio to seven products. Financial terms remain undisclosed, but the move is designed to ensure more Chinese patients get timely, life-saving treatment.
Listen in comfort:
Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn
Advertise on DNN:
advertise@thednn.ai
This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.
View sources & latest updates:
https://sources.thednn.ai/6668a6b0a8d89159